| Company Name: | Sanofi-Aventis ADS | | Ticker Symbol: | SNY | | | WWW Address: | www.sanofi-aventis.com | | CEO: | Christopher Viehbacher | | No. of Employees: | 98,213 | | Common Issue Type: | AD | | Business Description: | A global pharmaceutical group, which is engaged in the research, development, manufacture and marketing of healthcare products.
|
| | | Industry Information: | DRUGS - Drug Manufacturers - Major [more like this] |
| | Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 39.42 |  0.79 | 39.4 | 39.42 | 39.26 | 38.78 | 38.33 | 600939 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 103,718.0 | 2,631.1 | 0.87 | 2.04 | 1.62 | 18.9 | 3.7 | 40.17 - 24.59 |
| | KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 38.63 | $ | | PE Ratio - LTM | 18.9 | |
| Market Capitalisation | 101,640.0 | mil |
| Latest Shares Outstanding | 2,631.1 | mil |
| Earnings pS (EPS) | 2.04 | $ |
| Dividend pS (DPS) | 1.62 | ¢ |
| Dividend Yield | 3.7 | % |
| Dividend Payout Ratio | 79 | % |
| Revenue per Employee | 407,858 | $ |
| Effective Tax Rate | 12.6 | % |
| Float | 0.0 | mil |
| Float as % of Shares Outstanding | 0.0 | % |
| Foreign Sales | 21,507 | mil |
| Domestic Sales | 16,814 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 0.00 | % |
| Research & Devlopment (R&D) as % of Revenue | 0.00 | % |
| Gross Profit Margin | 0.0 | % |
| EBITDA Margin | 0.0 | % |
| Pre-Tax Profit Margin | 0.0 | % |
| Assets Turnover | 0.0 | % |
| Return on Assets (ROA) | 0.0 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | 0.0 | % |
| Current Ratio | 1.7 | |
| Leverage Ratio (Assets/Equity) | 1.7 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.22 | |
| LT Debt/Total Capital | 14.0 | % |
| Working Capital pS | 4.13 | $ |
| Cash pS | 3.31 | $ |
| Book-Value pS | 23.79 | $ |
| Tangible Book-Value pS | 0.01 | $ |
| Cash Flow pS | 5.43 | $ |
| Free Cash Flow pS | 1.42 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 1.62 | |
| Price/Tangible Book Ratio | 3623.01 | |
| Price/Cash Flow | 7.1 | |
| Price/Free Cash Flow | 27.3 | |
| P/E as % of Industry Group | 84.0 | % |
| P/E as % of Sector Segment | 110.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Dividend Declared Date | 02/12/2009 |
| Dividend Ex-Date | 04/19/2009 |
| Dividend Record Date | 04/21/2009 |
| Dividend Pay Date | 12/31/1899 |
| Dividend Amount | 1418 |
| Type of Payment | Cash Payment |
| Dividend Rate | 1.42 |
| Current Dividend Yield | 3.7 |
| 5-Y Average Dividend Yield | 3.1 |
| Payout Ratio | 79.0 |
| 5-Y Average Payout Ratio | 47.0 |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | | | | | PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 2.5 | 101 | 11,485 | 21,733 |
| 4 Weeks | 39.07 | 35.83 | 36.92 | 4.6 | 98 | 12,697 | 215,850 |
| 13 Weeks | 40.17 | 32.91 | 34.53 | 11.9 | 104 | 14,474 | 882,902 |
| 26 Weeks | 40.17 | 27.90 | 31.69 | 21.9 | 101 | 18,459 | 2,307,390 |
| 52 Weeks | 40.17 | 24.59 | 27.66 | 39.7 | 113 | 19,954 | 4,968,461 |
| YTD | 40.17 | 24.59 | - | 20.1 | 98 | 20,132 | 4,569,977 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 38.20 | 38.26 | 37.87 | 33.99 | 32.15 | 0.87 | 0.87 |
| | | | GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 30.21 | 76.9 | 6.25 |
| Income | 0.00 | 0.0 | 28.68 |
| Dividend | 24.60 | 92.2 | 26.70 |
| Capital Spending | 8.34 | NA | 14.03 |
| R&D | 17.58 | NA | 10.27 |
| Normalized Inc. | 0.00 | NA | 13.76 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | -6.1 | 48.9 | -6.1 |
| Earnings % | -46.1 | -69.9 | -22.4 |
| EPS % | -28.1 | -100.0 | -28.1 |
| EPS $ | -0.80 | -0.74 | -0.80 |
| | | | SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 8.42 |
| Current Ratio | 1.6 |
| Quick Ratio (Acid Test) | 1.1 |
| Liquidity Ratio (Cash) | 0.50 |
| Receivables Turnover | 4.6 |
| Average Collection Period | 78 |
| Working Capital/Equity | 13.5 |
| Working Capital pS | 3.20 |
| Cash-Flow pS | 5.43 |
| Free Cash-Flow pS | 1.87 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 2.52 |
| Financial Leverage Ratio (Assets/Equity) | 1.6 |
| Debt Ratio | 37.7 |
| Total Debt/Equity (Gearing Ratio) | 0.13 |
| LT Debt/Equity | 0.09 |
| LT Debt/Capital Invested | 36.2 |
| LT Debt/Total Liabilities | 15.4 |
| Interest Cover | 15.8 |
| Interest/Capital Invested | 0.53 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 7.31 |
| Tobin's Q Ratio | 1.02 |
| Current P/E Ratio - LTM | 18.90 |
| Enterprise Value (EV)/EBITDA | 8.04 |
| Enterprise Value (EV)/Free Cash Flow | 27.43 |
| Dividend Yield | 3.7 |
| Price/Tangible Book Ratio - LTM | 3623.01 |
| Price/Book Ratio - LTM | 1.62 |
| Price/Cash Flow Ratio | 7.1 |
| Price/Free Cash Flow Ratio - LTM | 27.3 |
| Price/Sales Ratio | 2.54 |
| P/E Ratio (1 month ago) - LTM | 19.2 |
| P/E Ratio (26 weeks ago) - LTM | 15.5 |
| P/E Ratio (52 weeks ago) - LTM | 10.6 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 0 |
| P/E as % of Industry Group | 84.0 |
| P/E as % of Sector Segment | 110.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 14.0 |
| PER SHARE FIGURES |
| LT Debt pS | 2.20 |
| Current Liabilities pS | 4.94 |
| Tangible Book Value pS - LTM | 0.01 |
| Book Value pS - LTM | 23.79 |
| Capital Invested pS | 25.91 |
| Cash pS - LTM | 3.31 |
| Cash Flow pS - LTM | 5.43 |
| Free Cash Flow pS - LTM | 1.42 |
| Earnings pS (EPS) | 2.04 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | 12.31 |
| Free Cash Flow Margin 5YEAR AVG | -6.91 |
| Net Profit Margin | 14.9 |
| Net Profit Margin - 5YEAR AVRG. | 9.5 |
| Equity Productivity | 0.64 |
| Return on Equity (ROE) | 9.6 |
| Return on Equity (ROE) - 5YEAR AVRG. | 5.7 |
| Capital Invested Productivity | 0.59 |
| Return on Capital Invested (ROCI) | 8.8 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 5.1 |
| Assets Productivity | 0.40 |
| Return on Assets (ROA) | 6.0 |
| Return on Assets (ROA) - 5YEAR AVRG. | 3.3 |
| Gross Profit Margin | 0.0 |
| Gross Profit Margin - 5YEAR AVRG. | 80.4 |
| EBITDA Margin - LTM | 0.0 |
| EBIT Margin - LTM | 0.0 |
| Pre-Tax Profit Margin | 18.8 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 13.4 |
| Effective Tax Rate | 12.6 |
| Effective Tax Rate - 5YEAR AVRG. | 5.0 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 345 |
| Revenue per Employee | 407,858 |
| Net Income per Employee | 60,746 |
| Average Collection Period | 66 |
| Receivables Turnover | 4.6 |
| Day's Inventory Turnover Ratio | 279 |
| Inventory Turnover | 1.3 |
| Inventory/Sales | 12.5 |
| Accounts Payble/Sales | 9.69 |
| Assets/Revenue | 2.50 |
| Net Working Capital Turnover | 4.76 |
| Fixed Assets Turnover | 0.51 |
| Total Assets Turnover | 0.4 |
| Revenue per $ Cash | 6.82 |
| Revenue per $ Plant | 4.14 |
| Revenue per $ Common Equity | 0.64 |
| Revenue per $ Capital Invested | 0.59 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 26.1 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 27.5 |
| Research & Devlopment (R&D) as % of Revenue | 15.9 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 15.9 |
|
|  
| | |  |  | |
| |